← Browse by Condition
Medical Condition

hematopoietic and lymphoid system neoplasm

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for hematopoietic and lymphoid system neoplasm sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hematopoietic and lymphoid system neoplasm Clinical Trials

How many clinical trials are currently recruiting for hematopoietic and lymphoid system neoplasm?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for hematopoietic and lymphoid system neoplasm, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hematopoietic and lymphoid system neoplasm?
hematopoietic and lymphoid system neoplasm research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hematopoietic and lymphoid system neoplasm clinical trial?
Eligibility criteria for hematopoietic and lymphoid system neoplasm trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Mayo Clinic 1 trial
City of Hope Medical Center 1 trial
Roswell Park Cancer Institute 1 trial

Recruiting Clinical Trials

NCT05411523
Recruiting

Assessing Effect of Spinal Cord Stimulation on Pain and Quality of Life With Chemotherapy-Induced Peripheral Neuropathy

Enrollment
20 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT06059391 Phase 2
Recruiting

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Enrollment
216 pts
Location
United States
Sponsor
City of Hope Medical Center
View Trial →
NCT05893940
Recruiting

Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients

Enrollment
75 pts
Location
United States
Sponsor
Roswell Park Cancer Institute
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology